Protagonist Therapeutics price target lowered to $33 from $50 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Protagonist Therapeutics to $33 from $50 and keeps a Buy rating on the shares. With its Q3 earnings, Protagonist indicated that the company was making the development of rusfertide in polycythemia vera as its singular strategic focus, Tsao tells investors in a research note.